DNAprint Genomics (DNAG)

[mingwan0]

Remember Lonnie Bookbinder?

http://www.sema4usa.com/Company/events/LifeSciences2002.htm

Semaphore Dedicates Life Sciences Diligence Practice

Firm emphasizes and expands Technology and Sciences diligence to Bio/Pharma markets.

(Boston- London- Zurich) Sema4, Inc. (Semaphore) announces the expansion of its Technology Diligence practice. Stating that Semaphore clients are experiencing greater activity in the Life Sciences markets, Semaphore CEO Mark S. DiSalvo states “We thought it appropriate to greater emphasize the skills and resources we have to provide assurance and Independent Verification and Validation in the Life Sciences and Bio/Pharma markets, especially since our clients are asking us to perform this level of assurance.”

This dedicated Life Sciences business practice was created to provide visibility and clarity to the decision-making process. “It facilitates informed judgments on risk and opportunity. The Life Sciences are often subject to misunderstanding, misapplication and misrepresentation,” said DiSalvo. DiSalvo explained that this confusion has a deleterious effect on productivity in even the most business savvy environments. Semaphore research has discovered that when Technology Diligence is applied prior to, or in concert with, a funding event it provides appropriate and necessary discipline to the judgment process. The result allows for increased confidence in the decision contemplated and executed. Research confirms that Bio/Pharma projects such as drug development are nearly always over budget, behind schedule, or are abandoned completely. Facts are that the FDA approves less than 2% of the drug pipeline. Those that do receive approval often are not commercially successful. Semaphore services in this space include Clinical Trial review, FDA compliance and certification process monitoring, proof of science concept, and acquisition target validation.

The firm has significantly expanded its resources globally in the Life Sciences space. Richard Gabriel former CEO of Calix Corporation is the point person for the firm as head of Life Sciences diligence services practice. “I am delighted to join the quality team represented by Semaphore. Its skills providing real-world diligence from Emerging Technologies to Enterprise Software to Life Sciences are legendary,” he added. His team includes: Hector Gomez, MD, Ph.D, former CEO of Transcend Therapeutics, Inc. and Lonnie Bookbinder, Ph.D, an experienced large Pharma executive. “The strength of this dedicated team will offer our clients the clearest direction and best assurance of success possible. We bring hard science and business savvy to the table every day,” Gabriel added.

For any new investors, Richard Gabriel is the DNAP CEO/President and Hector Gomez is the DNAP CHasirman and Chief Medical Officer, hence the interest in what Dr. Bookbinder gets up to. We always found it difficult to find out much about Lonnie (leaving aside Lewis & Clark expedition and Ribi Group disgruntled investor related bits and pieces). Here's something I came across today though:

http://66.102.9.104/search?q=cache:_UE3ehBGgqUJ:www.efeckta.com/company.php3+%22lonnie+bookbinder%22...

Lonnie Bookbinder, PhD – Vice President, Marketing

Dr. Bookbinder has over 30 years experience in the biopharmaceutical industry. Lonnie has a BS in Biological Sciences, and has done post-grad work in Pharmacology, Clinical Research, Toxicology, earning an MBA and Ph.D. in Business Management. He has served as Chief Operating Officer, CellPath, a start-up drug discovery company; Vice-President Corporate Development, at Ribi ImmunoChem, a cancer vaccine development company; Vice-President Corporate Development, at Nycomed-Salutar, a drug development company. In addition, he served as Director, OEM agreements at In-Vivo Business Unit, Immunomedics, and key account executive at Lederle Labs.

This is from a cached page for this site, the current page does not have Lonnie suggesting that he is perhaps no longer with the company concerned. It does provide a bit more background though.